Monopar Therapeutics
1000 Skokie Blvd., Suite 350
Wilmette
Illinois
60091
United States
Email: info@monopartherapeutics.com
81 articles about Monopar Therapeutics
-
Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
3/28/2024
Monopar Therapeutics Inc. announced fourth quarter and full-year 2023 financial results and summarized recent developments.
-
Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
3/5/2024
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, announced positive preclinical imaging data of a therapeutic radioisotope bound to its proprietary uPAR targeting agent MNPR-101.
-
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
2/27/2024
Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that the internationally recognized radiopharmaceutical physician, Professor Rodney Hicks, will be the lead investigator for Monopar’s MNPR-101-Zr Phase 1 dosimetry clinical trial in advanced cancer patients.
-
Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
2/22/2024
Monopar Therapeutics Inc. today announced promising preclinical imaging and therapeutic efficacy data for its MNPR-101 radiopharmaceutical program.
-
Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments
11/9/2023
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, announced third quarter 2023 financial results and summarized recent developments.
-
Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
11/1/2023
Monopar Therapeutics Inc. will present data from its ongoing Phase 1b open-label, dose-escalating clinical trial of camsirubicin in patients with advanced soft tissue sarcoma later at the 2023 Connective Tissue Oncology Society Annual Meeting, which is bringing together the world’s leading sarcoma specialists.
-
Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
9/5/2023
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, announced that Chandler D. Robinson, MD, Monopar’s Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference.
-
Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments
8/10/2023
Monopar Therapeutics Inc. today announced second quarter 2023 financial results and summarized recent developments.
-
Monopar Provides Encouraging Camsirubicin Clinical Data Update - August 08, 2023
8/8/2023
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, provided an update from its currently enrolling multi-center open-label Phase 1b clinical trial of camsirubicin in patients with advanced soft tissue sarcoma.
-
Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore
7/11/2023
Monopar Therapeutics Inc. announced a collaboration with the Cancer Science Institute of Singapore at the National University of Singapore to evaluate radiopharmaceutical versions of MNPR-101 in several aggressive cancers.
-
Monopar to Participate in the Radiopharma Forum by the Lake 2023
6/21/2023
Monopar Therapeutics Inc. today announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will participate in a panel discussion at the “Radiopharma Forum by the Lake” on Monday June 26, 2023, at 6:15pm CT at the Chicago Club.
-
Monopar to Participate in the Maxim Group’s Healthcare Virtual Conference
6/14/2023
Monopar Therapeutics Inc. announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will participate in a one-on-one fireside chat with Jason McCarthy, PhD, Senior Managing Director of Equity Research, at the Maxim Group’s Healthcare Virtual Conference on Tuesday June 20, 2023 at 1:30pm ET.
-
Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update
6/1/2023
Monopar Therapeutics Inc. today announced an update from its currently enrolling multi-center open-label Phase 1b clinical trial of camsirubicin in patients with advanced soft tissue sarcoma (ASTS).
-
Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments
5/11/2023
Monopar Therapeutics Inc., a clinicalstage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, announced first quarter 2023 financial results and summarized recent developments.
-
Monopar Therapeutics is dropping its lead candidate, Validive, after it failed to meet efficacy markers in Phase IIb/III trials for severe oral mucositis.
-
Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis
3/27/2023
Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced completion of a pre-specified interim analysis for its Validive Phase 2b/3 VOICE trial for the prevention of severe oral mucositis (SOM) in patients undergoing chemoradiotherapy (CRT) for oropharyngeal cancer (OPC).
-
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments
3/23/2023
Monopar Therapeutics Inc. today announced fourth quarter and full-year 2022 financial results and summarized recent developments.
-
Monopar to Present at the 35th Annual Roth Conference
3/7/2023
Monopar Therapeutics Inc. announced that Chandler Robinson, MD, Monopar’s Chief Executive Officer, will participate in a fireside chat at the 35th Annual Roth Conference.
-
Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials
2/27/2023
Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, Ill.) and NorthStar Medical Radioisotopes, LLC (Beloit, Wis.), today announced an expansion of their radiopharmaceutical collaboration along with a new radiolabeled MNPR-101 imaging candidate designated as MNPR-101-Zr.
-
Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin
2/14/2023
Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the following update on its currently enrolling open-label Phase 1b camsirubicin Maximum Tolerated Dose (MTD) trial in patients with advanced soft tissue sarcoma (ASTS).